New Clinical Trial Data on Crohn’s Disease Treatment Filgotinib Reported by Galapagos

New Clinical Trial Data on Crohn’s Disease Treatment Filgotinib Reported by Galapagos
Beglium-based Galapagos NV recently reported additional data from its Phase 2 FITZROY clinical trial assessing filgotinib, a selective JAK1 inhibitor being investigated for the treatment of Crohn’s disease. The FITZROY trial assessed the efficacy and safety of filgotinib (200 mg once daily) versus placebo in 174 patients with moderate to severe active Crohn’s disease, either anti-TNF naive or anti-TNF failures. In

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

Leave a Comment

Your email address will not be published. Required fields are marked *